209 related articles for article (PubMed ID: 25461323)
1. Discovery of novel VEGFR-2 inhibitors. Part II: biphenyl urea incorporated with salicylaldoxime.
Gao H; Su P; Shi Y; Shen X; Zhang Y; Dong J; Zhang J
Eur J Med Chem; 2015 Jan; 90():232-40. PubMed ID: 25461323
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel VEGFR-2 inhibitors. Part 5: Exploration of diverse hinge-binding fragments via core-refining approach.
Shan Y; Gao H; Shao X; Wang J; Pan X; Zhang J
Eur J Med Chem; 2015 Oct; 103():80-90. PubMed ID: 26342134
[TBL] [Abstract][Full Text] [Related]
3. Discovery of biphenyl-aryl ureas as novel VEGFR-2 inhibitors. Part 4: exploration of diverse hinge-binding fragments.
Su P; Wang J; Shi Y; Pan X; Shao R; Zhang J
Bioorg Med Chem; 2015 Jul; 23(13):3228-36. PubMed ID: 25982075
[TBL] [Abstract][Full Text] [Related]
4. Biphenyl derivatives incorporating urea unit as novel VEGFR-2 inhibitors: design, synthesis and biological evaluation.
Wang C; Gao H; Dong J; Zhang Y; Su P; Shi Y; Zhang J
Bioorg Med Chem; 2014 Jan; 22(1):277-84. PubMed ID: 24315192
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of tumor cell growth and angiogenesis by 7-aminoalkoxy-4-aryloxy-quinazoline ureas, a novel series of multi-tyrosine kinase inhibitors.
Ravez S; Barczyk A; Six P; Cagnon A; Garofalo A; Goossens L; Depreux P
Eur J Med Chem; 2014 May; 79():369-81. PubMed ID: 24747748
[TBL] [Abstract][Full Text] [Related]
6. Discovery of biphenyl-based VEGFR-2 inhibitors. Part 3: design, synthesis and 3D-QSAR studies.
Lu W; Li P; Shan Y; Su P; Wang J; Shi Y; Zhang J
Bioorg Med Chem; 2015 Mar; 23(5):1044-54. PubMed ID: 25637123
[TBL] [Abstract][Full Text] [Related]
7. Discovery of N-(2-phenyl-1H-benzo[d]imidazol-5-yl)quinolin-4-amine derivatives as novel VEGFR-2 kinase inhibitors.
Shi L; Wu TT; Wang Z; Xue JY; Xu YG
Eur J Med Chem; 2014 Sep; 84():698-707. PubMed ID: 25064347
[TBL] [Abstract][Full Text] [Related]
8. Indoline ureas as potential anti-hepatocellular carcinoma agents targeting VEGFR-2: Synthesis, in vitro biological evaluation and molecular docking.
Eldehna WM; Fares M; Ibrahim HS; Aly MH; Zada S; Ali MM; Abou-Seri SM; Abdel-Aziz HA; Abou El Ella DA
Eur J Med Chem; 2015 Jul; 100():89-97. PubMed ID: 26071861
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of thienopyrimidine urea derivatives with potential cytotoxic and pro-apoptotic activity against breast cancer cell line MCF-7.
Abdelhaleem EF; Abdelhameid MK; Kassab AE; Kandeel MM
Eur J Med Chem; 2018 Jan; 143():1807-1825. PubMed ID: 29133058
[TBL] [Abstract][Full Text] [Related]
11. Pharmacophore based 3D-QSAR modeling and free energy analysis of VEGFR-2 inhibitors.
Rajagopalan M; Balasubramanian S; Ramaswamy A; Mathur PP
J Enzyme Inhib Med Chem; 2013 Dec; 28(6):1236-46. PubMed ID: 23061928
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, in silico and antiproliferative evaluation of novel pyrazole derivatives as VEGFR-2 inhibitors.
Ravula P; Vamaraju HB; Paturi M; Sharath Chandra JNGN
Arch Pharm (Weinheim); 2018 Jan; 351(1):. PubMed ID: 29205467
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel VEGFR-2 inhibitors embedding 6,7-dimethoxyquinazoline and diarylamide fragments.
Wang R; Liu H; You YY; Wang XY; Lv BB; Cao LQ; Xue JY; Xu YG; Shi L
Bioorg Med Chem Lett; 2021 Mar; 36():127788. PubMed ID: 33460739
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and molecular docking of novel indole scaffold-based VEGFR-2 inhibitors as targeted anticancer agents.
Roaiah HM; Ghannam IAY; Ali IH; El Kerdawy AM; Ali MM; Abbas SE; El-Nakkady SS
Arch Pharm (Weinheim); 2018 Feb; 351(2):. PubMed ID: 29323750
[TBL] [Abstract][Full Text] [Related]
15. Novel pyrazolopyrimidine urea derivatives: Synthesis, antiproliferative activity, VEGFR-2 inhibition, and effects on the cell cycle profile.
Kassab AE; El-Dash Y; Gedawy EM
Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900319. PubMed ID: 32091161
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and molecular docking of novel 2-arylbenzothiazole multiangiokinase inhibitors targeting breast cancer.
Abdel-Mohsen HT; Abd El-Meguid EA; El Kerdawy AM; Mahmoud AEE; Ali MM
Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900340. PubMed ID: 32045054
[TBL] [Abstract][Full Text] [Related]
17. Discovery of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors: Design, synthesis, and anti-proliferative evaluation.
Eissa IH; El-Helby AA; Mahdy HA; Khalifa MM; Elnagar HA; Mehany ABM; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; El-Adl K
Bioorg Chem; 2020 Dec; 105():104380. PubMed ID: 33128967
[TBL] [Abstract][Full Text] [Related]
18. Design and discovery of 4-anilinoquinazoline-urea derivatives as dual TK inhibitors of EGFR and VEGFR-2.
Zhang HQ; Gong FH; Ye JQ; Zhang C; Yue XH; Li CG; Xu YG; Sun LP
Eur J Med Chem; 2017 Jan; 125():245-254. PubMed ID: 27688180
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, molecular docking, and anticancer evaluations of 1-benzylquinazoline-2,4(1H,3H)-dione bearing different moieties as VEGFR-2 inhibitors.
El-Adl K; El-Helby AA; Sakr H; El-Hddad SSA
Arch Pharm (Weinheim); 2020 Aug; 353(8):e2000068. PubMed ID: 32510731
[TBL] [Abstract][Full Text] [Related]
20. Exploration of carbamide derived pyrimidine-thioindole conjugates as potential VEGFR-2 inhibitors with anti-angiogenesis effect.
Sana S; Reddy VG; Bhandari S; Reddy TS; Tokala R; Sakla AP; Bhargava SK; Shankaraiah N
Eur J Med Chem; 2020 Aug; 200():112457. PubMed ID: 32422489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
